WIXOM, Mich., Dec. 3, 2018 /PRNewswire/ -- Rockwell
Medical, Inc. (NASDAQ: RMTI) (the "Company" or "Rockwell Medical")
today announced that Charlie Shiner
has been appointed Vice President, Marketing, effective
immediately. Mr. Shiner will report to Stuart Paul, President & Chief Executive
Officer of the Company.
Mr. Shiner joins Rockwell Medical from Otsuka Pharmaceuticals,
Ltd., a global pharmaceuticals company focused on the development
and marketing of products for the diagnosis and treatment of
diseases related to the central nervous system, oncology,
gastroenterology, ophthalmology and cardiovascular areas. He most
recently served as the marketing franchise leader for Otsuka's
renal portfolio, where he successfully launched Otsuka's new
therapeutic Jynarque and managed other key renal therapeutics.
Previously, he held the roles of Director and Senior Product
Manager, Digital Marketing at Otsuka America Pharmaceuticals. In
these roles, Mr. Shiner was responsible for the digital marketing
of cardio-renal products across applicable professional and
consumer channels. Earlier in his career, Mr. Shiner spent 11 years
at Pfizer, Inc. where among other roles, he worked to identify and
execute upon strategic opportunities for Pfizer's clinical
treatments within hospital accounts across the United States. Mr. Shiner holds a B.S. in
Business Administration from the University of
California, Riverside and an M.B.A from Northern Illinois University.
Mr. Paul stated, "We are pleased to welcome Charlie, a seasoned
marketing professional, to Rockwell Medical. This is a pivotal time
for our Company as we prepare for the U.S. commercial launch of
Dialysate Triferic in the first half of 2019, and we are fortunate
to have someone of Charlie's caliber now on board leading our
marketing efforts. Charlie has a deep understanding of the renal
space and the expertise needed to develop an effective marketing
plan that will enable Rockwell Medical to realize the full value of
Triferic, as well as, reach physicians and patients across the
U.S."
Mr. Shiner said, "Given my marketing experience in the renal
industry, I was drawn to Rockwell Medical, because of the
significant potential of Dialysate Triferic and IV Triferic to
positively impact patients in the dialysis community and global
anemia market. I am energized by the opportunity to work alongside
Stuart and the team to realize the full potential of the Company's
products."
About Rockwell Medical, Inc.
Rockwell Medical is a biopharmaceutical company targeting
end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Rockwell Medical's exclusive renal drug therapies support disease
management initiatives to improve the quality of life and care of
dialysis patients and are intended to deliver safe and effective
therapy, while decreasing drug administration costs and improving
patient convenience. Rockwell Medical's anemia drug Triferic is the
only FDA-approved product indicated for iron replacement and
maintenance of hemoglobin in hemodialysis patients. Rockwell's FDA
approved generic drug Calcitriol (active vitamin D) is for treating
secondary hyperparathyroidism in patients undergoing chronic renal
dialysis. Rockwell Medical is also an established manufacturer,
supplier and leader in delivering high-quality hemodialysis
concentrates/dialysates (used to maintain human life by removing
toxins and replacing critical nutrients in the dialysis patient's
bloodstream) to dialysis providers and distributors in the U.S. and
abroad. Please visit www.rockwellmed.com for more information.
Forward-Looking Statement
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the federal
securities laws, including, but not limited to, Rockwell's
intention to bring to market Triferic, IV Triferic and Calcitriol.
Words such as "may," "might," "will," "should," "believe,"
"expect," "anticipate," "estimate," "continue," "could," "plan,"
"potential," "predict," "forecast," "project," "plan", "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. While
Rockwell believes these forward-looking statements are reasonable,
undue reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties (including, without limitation, those set
forth in Rockwell's SEC filings), many of which are beyond our
control and subject to change. Actual results could be materially
different. Risks and uncertainties include: statements about the
timing and success of our planned NDA submission for IV Triferic;
the potential market opportunity for IV Triferic and other Rockwell
products; pricing and reimbursement status for IV Triferic,
Triferic and other Rockwell products, including eligibility for
add-on reimbursement under TDAPA; liquidity and capital resources;
expected duration of Rockwell Medical's existing working capital;
plans and timing relating to the planned commercialization of
Triferic; and timing and success of our efforts to renegotiate
economic terms of our concentrate business Rockwell expressly
disclaims any obligation to update or alter any statements whether
as a result of new information, future events or otherwise, except
as required by law.
Contacts
Dan Katcher / Kelly Sullivan / Arielle
Rothstein
Joele Frank, Wilkinson Brimmer
Katcher
212-355-4449
View original
content:http://www.prnewswire.com/news-releases/rockwell-medical-inc-appoints-new-vice-president-marketing-300759254.html
SOURCE Rockwell Medical, Inc.